Company · egalet-ltd-e8dca57a
Egalet Ltd
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Egalet Ltd. Companies, record egalet-ltd-e8dca57a. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/egalet-ltd-e8dca57a
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Egalet Ltd
- Trials
- 20
- As lead sponsor
- 20
- As collaborator
- 0
- Recruiting
- 0
- Active, recruiting or not
- 0
- Completed
- 19
- Stopped early, withdrawn or suspended
- 1
- Posted results
- 6
- Trials by phase
- Phase 1 11, Phase 2 4, Phase 3 5
- Drugs its trials test
- 11
- Comparisons calculated in its trials
- 11
- First trial registered
- 2005-12-19
- Last update
- 2018-03-06
Source ClinicalTrials.gov
Pipeline11
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| KETOROLAC TROMETHAMINE | Phase 3 | 13 | 13 | 0 | PTGS1, PTGS2 | Cyclooxygenase inhibitor | https://conductscience.org/library/drugs/CHEMBL1201124 | Open Targets |
| OXYCODONE | Phase 3 | 2 | 2 | 0 | OPRM1 | Mu opioid receptor agonist | https://conductscience.org/library/drugs/CHEMBL656 | Open Targets |
| CARVEDILOL | Phase 2 | 1 | 1 | 0 | ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, ADRB3 | Adrenergic receptor alpha-1 antagonist; Adrenergic receptor beta antagonist | https://conductscience.org/library/drugs/CHEMBL723 | Open Targets |
| MORPHINE SULFATE | Phase 2 | 1 | 1 | 0 | OPRM1 | Mu opioid receptor agonist | https://conductscience.org/library/drugs/CHEMBL2103744 | Open Targets |
| FLUTICASONE PROPIONATE | Phase 1 | 2 | 2 | 0 | NR3C1 | Glucocorticoid receptor agonist | https://conductscience.org/library/drugs/CHEMBL1473 | Open Targets |
| LIDOCAINE HYDROCHLORIDE | Phase 1 | 2 | 2 | 0 | SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | Sodium channel alpha subunit blocker | https://conductscience.org/library/drugs/CHEMBL1200409 | Open Targets |
| OXYMETAZOLINE HYDROCHLORIDE | Phase 1 | 2 | 2 | 0 | ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C | Adrenergic receptor alpha agonist | https://conductscience.org/library/drugs/CHEMBL1200791 | Open Targets |
| ACETAMINOPHEN | Phase 1 | 1 | 1 | 0 | FAAH, PTGS1, PTGS2, TRPV1 | Anandamide amidohydrolase inhibitor; Cyclooxygenase inhibitor; Vanilloid receptor opener | https://conductscience.org/library/drugs/CHEMBL112 | Open Targets |
| HYDROCODONE | Phase 1 | 1 | 1 | 0 | OPRD1, OPRK1, OPRM1 | Opioid receptors; mu/kappa/delta agonist | https://conductscience.org/library/drugs/CHEMBL1457 | Open Targets |
| MORPHINE | Phase 1 | 1 | 1 | 0 | OPRM1 | Mu opioid receptor agonist | https://conductscience.org/library/drugs/CHEMBL70 | Open Targets |
1 to 10 of 11
See all 11 pipelineTrials20
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02716857 | Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain | Lead sponsor | Phase 3 | Completed | Interventional | 549 | 2016-03 | OXYCODONE | https://conductscience.org/library/trials/NCT02716857 | ClinicalTrials.gov | |
| NCT02603705 | Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain | Lead sponsor | Phase 3 | Completed | Interventional | 281 | 2016-03-07 | OXYCODONE | https://conductscience.org/library/trials/NCT02603705 | ClinicalTrials.gov | |
| NCT02102516 | SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures | Lead sponsor | Phase 3 | Completed | Interventional | 45 | 2014-03 | KETOROLAC TROMETHAMINE | https://conductscience.org/library/trials/NCT02102516 | ClinicalTrials.gov | |
| NCT01365650 | Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis | Lead sponsor | Phase 1 | Completed | Interventional | 24 | 2007-12 | 2015-07-23 | FLUTICASONE PROPIONATE, KETOROLAC TROMETHAMINE, OXYMETAZOLINE HYDROCHLORIDE | https://conductscience.org/library/trials/NCT01365650 | ClinicalTrials.gov |
| NCT01365611 | Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects | Lead sponsor | Phase 1 | Completed | Interventional | 36 | 2007-02 | 2013-04-30 | FLUTICASONE PROPIONATE, KETOROLAC TROMETHAMINE | https://conductscience.org/library/trials/NCT01365611 | ClinicalTrials.gov |
| NCT01363089 | Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine | Lead sponsor | Phase 1 | Completed | Interventional | 21 | 2007-01 | KETOROLAC TROMETHAMINE, OXYMETAZOLINE HYDROCHLORIDE | https://conductscience.org/library/trials/NCT01363089 | ClinicalTrials.gov | |
| NCT01363076 | The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years | Lead sponsor | Phase 1 | Completed | Interventional | 20 | 2007-06 | 2012-04-09 | KETOROLAC TROMETHAMINE | https://conductscience.org/library/trials/NCT01363076 | ClinicalTrials.gov |
| NCT01363063 | Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Interventional | 40 | 2006-12 | KETOROLAC TROMETHAMINE, LIDOCAINE HYDROCHLORIDE | https://conductscience.org/library/trials/NCT01363063 | ClinicalTrials.gov | |
| NCT01363050 | Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Interventional | 15 | 2006-01 | 2013-05-03 | KETOROLAC TROMETHAMINE | https://conductscience.org/library/trials/NCT01363050 | ClinicalTrials.gov |
| NCT01356225 | A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery | Lead sponsor | Phase 2 | Completed | Interventional | 80 | 2004-02 | KETOROLAC TROMETHAMINE | https://conductscience.org/library/trials/NCT01356225 | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsConditions12
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Pain | 6 |
| Healthy Volunteers | 3 |
| Postoperative Pain | 3 |
| Healthy Subjects | 2 |
| Allergic Rhinitis | 1 |
| Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine | 1 |
| Cancer | 1 |
| Dental Impaction | 1 |
| Hypertension | 1 |
| Migraine | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 conditionsPartners0
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
None in this release.
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/egalet-ltd-e8dca57a
GET https://conductscience.org/api/companies/v1/egalet-ltd-e8dca57a/pipeline